New treatment tested for rare Muscle-Weakening disease in kids

NCT ID NCT06149559

Recruiting now Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a medication called rozanolixizumab is safe and effective for children aged 2 to 18 with moderate to severe generalized myasthenia gravis (gMG), a rare autoimmune disease that causes muscle weakness. The trial will enroll 12 children who haven't responded well to standard treatments. Researchers will monitor side effects, measure how the drug affects disease symptoms and antibody levels, and track how the body processes the medication over 18 weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Mg0006 20081
RECRUITING

Taipei, Taiwan
Mg0006 20095
RECRUITING

Taipei, Taiwan
Mg0006 20339
RECRUITING

Ōbu, Japan
Mg0006 20340
RECRUITING

Fuchu-shi, Japan
Mg0006 20343
RECRUITING

Sagamihara, Japan
Mg0006 40144
RECRUITING

Milan, Italy
Mg0006 40155
RECRUITING

Warsaw, Poland
Mg0006 40290
RECRUITING

Bologna, Italy
Mg0006 40733
RECRUITING

Naples, Italy
Mg0006 40734
RECRUITING

Warsaw, Poland
Mg0006 40836
RECRUITING

Kocaeli, Turkey (Türkiye)
Mg0006 40841
RECRUITING

Altindağ/ankara, Turkey (Türkiye)
Mg0006 50574
WITHDRAWN

Denton, Texas, 76208, United States

Conditions

Explore the condition pages connected to this study.

GENERALIZED MYASTHENIA GRAVIS